Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 18Prostatic Neoplasms 6Carcinoma, Renal Cell 5Uveal Melanoma 4Sarcoma 4Histiocytoma, Malignant Fibrous 4Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Vulvar Neoplasms 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Urethral Neoplasms 2Thyroid Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Myelodysplastic Syndromes 2Liposarcoma 2Leukemia 2Gastrointestinal Stromal Tumors 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Carcinoma, Endometrioid 2Bone Neoplasms 2Vaginal Neoplasms 1Urogenital Neoplasms 1Ureteral Neoplasms 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1

Interventions

Hydroxyurea 7Bevacizumab 7Everolimus 6lutetium Lu 177 dotatate 4Magnetic Resonance Spectroscopy 4pembrolizumab 3abemaciclib 3Sunitinib 3Imatinib Mesylate 3vistusertib 2gallium Ga 68 dotatate 2arginyllysine 2aldesleukin 2Whole Body Imaging 2Specimen Handling 2Radiotherapy 2Octreotide 2Nivolumab 2Cyclophosphamide 2Amino Acids 290Y-octreotide, DOTA-Tyr(3)- 2vatalanib 1tozuleristide 1sargramostim 1regorafenib 1pasireotide 1neratinib 1fludarabine phosphate 1fludarabine 1dexamethasone acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Meningioma × CTLA-4 Antigen × Clear all
NCT02648997 2026-01-26

An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
40 enrolled 14 charts
CNS

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡